SETD2 (20/45, 44%), CSMD3 (6/15, 40%) and TP53 (17/45, 38%) gene co-alterations were the most common in NSCLC patients with BRAF class 1 alterations (n = 45) (Figure 4A), while TP53 (28/48, 58%), TTN (9/18, 50%) and CSMD3 (9/18, 50%) were the most commonly co-altered genes in patients with BRAF class 2 alterations (n = 48) (Figure 4B). This evidence concerns the gene BRAF and non-small cell lung carcinoma.